[email protected]/(408) 457-3700

About Bionure

Bionure is an early stage drug development company focused at developing BN201, a neuroprotective drug, for the treatment of multiple sclerosis and two orphan indications: optic neuritis (ON) and neuromyelitis optica (NMO). We have designed an orphan strategy to demonstrate neuroprotection in a clinical PoC in a rare indication, acute ON, for which we have been granted orphan designation - allowing fast-track development. This will be followed by early market entry in NMO and extension to subsequent indications including multiple sclerosis, amyotrophic lateral sclerosis (ALS) and glaucoma (GL). The compound is in regulatory preclinical development and has been shown to promote neuroprotection in several animal models (multiple sclerosis, optic neuritis, glaucoma) as well as remyelination in oligodendrocytes. The MoA of BN201 has been characterized and it has shown to cross the BBB.

You need to register as an accredited investor before we can show you the details of any investment opportunities.

VentureHealth is currently invite only.

Request An Invite!

Startup's Info

Therapeutic Areas:
CNS / Neurology